1236P - Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)
| Autor: | Cappuzzo, F., Soo, R., Hochmair, M., Schuler, M., Mok, T.S.K., Stehle, G., Cseh, A., Lorence, R.M., Linden, S., Forman, N.D., Tsai, C.-M. |
|---|---|
| Zdroj: | In Annals of Oncology 1 October 2016 27 Supplement 6:vi427-vi427 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|